Predictive markers of immune response in glioblastoma: hopes and facts

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for GBM. N. Engl. J. Med. 352(10), 987–996 (2005). •• Randomized clinical trial evaluates concomitant and adjuvant temozolomide in patients with glioblastoma (GBM). Standard of care.
  Medline CASGoogle Scholar
• 2. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in GBM in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009). •• Randomized clinical trial evaluates concomitant and adjuvant temozolomide in patients with GBM. Standard of care. Long-term follow-up.
  Medline CASGoogle Scholar
• 3. Tosoni A, Franceschi E, Poggi R, Brandes AA. Relapsed GBM: treatment strategies for initial and subsequent recurrences. Curr. Treat. Options Oncol. 17(9), 49 (2016).
  MedlineGoogle Scholar
• 4. Franceschi E, Lamberti G, Paccapelo A et al. Third-line therapy in recurrent GBM: is it another chance for bevacizumab? J. Neurooncol. 139(2), 383–388 (2018).
  Medline CASGoogle Scholar
• 5. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230), 56–61 (2015).
  Medline CASGoogle Scholar
• 6. Omuro A, Vlahovic G, Lim M et al. Nivolumab with or without ipilimumab in patients with recurrent GBM: results from exploratory Phase I cohorts of CheckMate 143. Neuro. Oncol. 20(5), 674–686 (2018). • A Phase I study evaluates combination between nivolumab and ipilimumab or nivolumab alone in patients with GBM.
  Medline CASGoogle Scholar
• 7. Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R et al. Neoadjuvant nivolumab modifies the tumour immune microenvironment in resectable GBM. Nat. Med. 25(3), 470–476 (2019).
  Medline CASGoogle Scholar
• 8. Reardon DA, Omuro A, Brandes AA et al. Randomized Phase III study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent GBM: checkMate 143. Neuro Oncol. 19(3.1), iii21 (2017). • Preliminary results of a randomized Phase III trial evaluating the PD1 inhibitor nivolumab in patients with GBM.
  Google Scholar
• 9. Lukas RV, Rodon J, Becker K et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neurooncol. 140(2), 317–328 (2018).
  Medline CASGoogle Scholar
• 10. Anna C Filley, Mario Henriquez, Mahua Dey. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8(53), 91779–91794 (2017).
  MedlineGoogle Scholar
• 11. Janning M, Kobus F, Babayan A et al. Determination of PD-L1 expression in circulating tumour cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors. Cancers (Basel) 11(6), E835 (2019).
  Medline CASGoogle Scholar
• 12. Kim KJ, Yang HK, Kim WH, Kang GH. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget 8(35), 58887–58902 (2017).
  MedlineGoogle Scholar
• 13. Arora S, Velichinskii R, Lesh RW et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumours. Adv. Ther. 36(10), 2638–2678 (2019).
  MedlineGoogle Scholar
• 14. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).
  Medline CASGoogle Scholar
• 15. Ozaki Y, Muto S, Takagi H et al. Tumour mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer Immunol. Immunother. 69(1), 127–134 (2020).
  Medline CASGoogle Scholar
• 16. Goodman AM, Kato S, Bazhenova L et al. Tumour mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16(11), 2598–2608 (2017).
  Medline CASGoogle Scholar
• 17. Chan TA, Yarchoan M, Jaffee E et al. Development of tumour mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30(1), 44–56 (2019).
  Medline CASGoogle Scholar
• 18. Park J, Kwon M, Kim KH et al. Immune checkpoint inhibitor-induced reinvigoration of tumour-infiltrating CD8(+) T cells is determined by their differentiation status in GBM. Clin Cancer Res. 25(8), 2549–2559 (2019).
  Medline CASGoogle Scholar
• 19. Louveau A, Smirnov I, Keyes TJ et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560), 337–341 (2015).
  Medline CASGoogle Scholar
• 20. Aspelund A, Antila S, Proulx ST et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212(7), 991–999 (2015).
  Medline CASGoogle Scholar
• 21. De Simone R, Giampaolo A, Giometto B et al. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J. Neuropathol. Exp. Neurol. 54(2), 175–187 (1995).
  MedlineGoogle Scholar
• 22. Aloisi F, Ria F, Penna G, Adorini L. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J. Immunol. 160(10), 4671–4680 (1998).
  Medline CASGoogle Scholar
• 23. Carson MJ, Sutcliffe JG, Campbell IL. Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J. Neurosci. Res. 55(1), 127–134 (1999).
  Medline CASGoogle Scholar
• 24. Perng P, Lim M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front. Oncol. 5, 153 (2015).
  MedlineGoogle Scholar
• 25. Vitkovic L, Maeda S, Sternberg E. Anti- inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation 9, 295–312 (2001).
  Medline CASGoogle Scholar
• 26. Gong D, Shi W, Yi SJ, Chen H, Groffen J, Heisterkamp N. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 13, 31 (2012).
  Medline CASGoogle Scholar
• 27. Wainwright DA, Balyasnikova IV, Chang AL et al. IDO expression in brain tumours increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18, 6110–6121 (2012).
  Medline CASGoogle Scholar
• 28. Uyttenhove C, Pilotte L, Théate I et al. Evidence for a tumoural immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).
  Medline CASGoogle Scholar
• 29. Zhang I, Alizadeh D, Liang J et al. Characterization of arginase expression in glioma-associated microglia and macrophages. PLoS ONE 11, e0165118 (2016).
  MedlineGoogle Scholar
• 30. Hawkins RA, O'Kane RL, Simpson IA, Vina JR. Structure of the blood–brain barrier and its role in the transport of amino acids. J. Nutr. 136, S218–S226 (2006).
  Medline CASGoogle Scholar
• 31. Okada H, Weller M, Huang R et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16(15), e534–e542 (2015).
  MedlineGoogle Scholar
• 32. Shi Y. Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol. Immunother. 67(10), 1481–1489 (2018).
  Medline CASGoogle Scholar
• 33. Bristol-Myers Squibb (2019). https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab-
  Google Scholar
• 34. Bristol-Myers Squibb (2019). https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did
  Google Scholar
• 35. Wei R, Guo L, Wang Q, Miao J, Kwok HF, Lin Y. Targeting PD-L1 protein: translation, modification and transport. Curr. Protein Pept. Sci. 20(1), 82–91 (2019).
  Medline CASGoogle Scholar
• 36. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14(4), 847–856 (2015).
  Medline CASGoogle Scholar
• 37. Nduom EK, Wei J, Yaghi NK et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 18(2), 195–205 (2016).
  Medline CASGoogle Scholar
• 38. Chen RQ, Liu F, Qiu XY, Chen XQ. The prognostic and therapeutic value of PD-L1 in glioma. Front. Pharmacol. 9, 1503 (2019).
  MedlineGoogle Scholar
• 39. Garber ST, Hashimoto Y, Weathers SP et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 18, 1357–1366 (2016).
  Medline CASGoogle Scholar
• 40. Hodges TR, Ott M, Xiu J et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 19, 1047–1057 (2017).
  Medline CASGoogle Scholar
• 41. Berghoff AS, Kiesel B, Widhalm G et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 19, 1460–1468 (2017).
  Medline CASGoogle Scholar
• 42. Weller M, Reardon D, Brandes AA et al. Nivolumab vs bevacizumab in patients with recurrent glioblastoma: exploratory analysis of MGMT methylation status and baseline corticosteroid use. Neuro Oncol. 21(S6), vi12 (2019). • Subgroups analyses of a randomized Phase III trial evaluating nivolumab or bevacizumab in recurrent GBM.
  Google Scholar
• 43. Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumour mutational burden. N. Engl. J. Med. 378(22), 2093–2104 (2018).
  Medline CASGoogle Scholar
• 44. Goodman AM, Kato S, Bazhenova L et al. Tumour mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16(11), 2598–2608 (2017).
  Medline CASGoogle Scholar
• 45. Labriola M, Zhu J, Gupta R et al. Characterization of tumour mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 37(S7), 589–589 (2019).
  MedlineGoogle Scholar
• 46. Zehir A, Benayed R, Shah RH et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23(6), 703–713 (2017).
  Medline CASGoogle Scholar
• 47. McDonald KA, Kawaguchi T, Qi Q et al. Tumour heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann. Surg. Oncol. 26(7), 2191–2199 (2019).
  MedlineGoogle Scholar
• 48. Johanns TM, Miller CA, Dorward IG et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6(11), 1230–1236 (2016).
  MedlineGoogle Scholar
• 49. Snyder A, Wolchok JD. Successful treatment of a patient with glioblastoma and a germline POLE mutation: where next? Cancer Discov. 6(11), 1210–1211 (2016).
  MedlineGoogle Scholar
• 50. Chamberlain MC, Kim BT. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J. Neurooncol. 133(3), 561–569 (2017).
  Medline CASGoogle Scholar
• 51. Ranjan S, Quezado M, Garren N et al. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer 18(1), 239 (2018).
  MedlineGoogle Scholar
• 52. AlHarbi M, Ali Mobark N, AlMubarak L et al. Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency. Oncologist 23(12), 1401–1406 (2018).
  Medline CASGoogle Scholar
• 53. Kurz SC, Cabrera LP, Hastie D et al. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 91(14), e1355–e1359 (2018).
  Medline CASGoogle Scholar
• 54. Draaisma K, Wijnenga MM, Weenink B et al. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol. Commun. 3, 88 (2015).
  MedlineGoogle Scholar
• 55. Hodges TR, Ott M, Xiu J et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 19(8), 1047–1057 (2017). • Review evaluates current knowledge about immunotherapy in patients with glioma.
  Medline CASGoogle Scholar
• 56. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumours with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 57. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 58. Marabelle A, Le DT, Ascierto PA et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol. 38(1), 1–10 (2020).
  Medline CASGoogle Scholar
• 59. Gorlia T, Stupp R, Brandes AA et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group Phase I and II clinical trials. Eur. J. Cancer 48(8), 1176–1184 (2012).
  MedlineGoogle Scholar
• 60. Franceschi E, Tosoni A, Minichillo S et al. PERNO study group. the prognostic roles of gender and O6-Methylguanine-DNA methyltransferase methylation status in glioblastoma patients: the female power. World Neurosurg. 112, e342–e347 (2018).
  MedlineGoogle Scholar
• 61. Brandes AA, Franceschi E, Paccapelo A et al. Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist 22(4), 432–437 (2017).
  Medline CASGoogle Scholar
• 62. Khan I, Waqas M, Shamim MS. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. J. Pak. Med. Assoc. 67(5), 816–817 (2017).
  MedlineGoogle Scholar
• 63. Bady P, Kurscheid S, Delorenzi M et al. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol. 135(4), 601–615 (2018).
  Medline CASGoogle Scholar
• 64. de Groot J, Penas-Prado M, Alfaro-Munoz KD et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. pii:noz185 (2019).
  Google Scholar
• 65. Pombo Antunes AR, Scheyltjens I, Duerinck J et al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife 9, pii: e52176 (2020).
  Google Scholar
• 66. Hsu SPC, Chen YC, Chiang HC et al. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors. J. Neurooncol. 146(3), 417–426 (2020).
  Medline CASGoogle Scholar
• 67. Duan S, Yuan G, Liu X et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun. 6, 10068 (2015).
  Medline CASGoogle Scholar
• 68. Zhao J, Chen AX, Gartrell RD et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med. 25(3), 462–469 (2019).
  MedlineGoogle Scholar